TransAtlantic Consumer Dialogue (TACD) resolution on copyright terms
TACD has issued a resolution on copyright terms, and measures to mitigate the harm from excessive terms. The TACD Press release follows:
WHO releases sketchy report on second meeting of Expert Working Group on R&D Financing
The World Health Organization just published a report on this week’s second meeting of the WHO Expert Working Group (EWG) on R&D Financing.
Civil Society letter to Members of the WHO Expert Working Group on R&D Financing
Today nine NGOs sent a letter the WHO Expert Working Group on R&D Financing. The letter focuses on issues about transparency, conflicts of interest, and EWG outcomes. The whole EWG seems to be going very badly right now, in part because of the US government and much of Northern Europe is working hand and glove with the pharmaceutical industry, and partly because the Gates Foundation is protecting big pharma and seems to have an ideological attachment to strong IPR.
The Netflix prize, about to be won
Apparently at least one entrant has qualified to win the $1 million Netflix grand prize. One can follow the progress of the teams on the Netflix Leaderboard: http://www.netflixprize.com/leaderboard.
Auren Hoffman on productivity gains from open source software
According to Rapleaf CEO and venture capitalist Auren Hoffman, open source software has dramatically increased the productivity of software engineers. In a June 23, 2009 article in Tech Crunch titled “Engineers Are The Best Deal – So Stock Up On Them,” Hoffman writes:
Switzerland’s intellectual property rules are often different from what you might expect
The US Department of State “2009 Investment Climate Statement for Switzerland” provides an interesting and often unexpected portrait of the intellectual property landscape for a country that is often a hard-liner in global IPR negotiations. Continue Reading
US guts transparency clause in PAHO R&D resolution
The PAHO negotiations on the R&D resolution has produced a new draft, which radically guts the provision on transparency of pharmaceutical industry economics.
The US opposed this language:
“(j) to develop, with input from Member States, a possible standard for disclosure of economic data for drug registered for sale, including disclosures of the costs of R&D, the prices of products, and the annual revenues from the sale of products.”
The US agreed to this language:
Meet the chief US ACTA negotiator: Kira Alvarez, the Deputy Assistant USTR for IP Enforcement
Kira Alvarez is the Deputy Assistant USTR for Intellectual Property Enforcement, and the chief US negotiator for ACTA. According to her Linkedin bio, as late as October 2008, right before the election, she was the Time Warner Vice President for Global Public Policy, and before that, she was a lobbyist for Ely Lilly, the pharmaceutical company. Continue Reading
2009: PAHO dispute over standards for transparency of economic data for pharmaceutical industry
Today the executive board of the Pan American Health Organization (PAHO) is considering a proposal to have more transparency of the economics of the pharmaceutical industry. (I have separately blogged about this on the Huffpo). Specifically, an amendment offered to a PAHO EB resolution on research, proposed the following:
Designing Prizes
I just finished a two day meeting in Manchester, England, in a meeting of Joe Stigltiz’s Initiative for Policy Dialogue (IPD) Task Force on Intellectual Property and Development. The meeting was held at the University of Manchester’s Brooks World Poverty Institute. The agenda and conference papers for the meeting are on the web here, including a paper on prizes I wrote with Tim Hubbard. Continue Reading